CN107207417A - 新方法 - Google Patents

新方法 Download PDF

Info

Publication number
CN107207417A
CN107207417A CN201580073130.0A CN201580073130A CN107207417A CN 107207417 A CN107207417 A CN 107207417A CN 201580073130 A CN201580073130 A CN 201580073130A CN 107207417 A CN107207417 A CN 107207417A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
trifluoromethyl
prodrug
aquaporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580073130.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·F·佩尔蒂埃
G·W·法尔
P·R·迈盖克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Errol Meeks
Original Assignee
Errol Meeks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Errol Meeks filed Critical Errol Meeks
Publication of CN107207417A publication Critical patent/CN107207417A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/145—Esters of phosphorous acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580073130.0A 2014-11-13 2015-11-13 新方法 Pending CN107207417A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462079541P 2014-11-13 2014-11-13
US62/079,541 2014-11-13
US201462080241P 2014-11-14 2014-11-14
US62/080,241 2014-11-14
PCT/US2015/060731 WO2016077787A1 (en) 2014-11-13 2015-11-13 Novel methods

Publications (1)

Publication Number Publication Date
CN107207417A true CN107207417A (zh) 2017-09-26

Family

ID=55955168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580073130.0A Pending CN107207417A (zh) 2014-11-13 2015-11-13 新方法

Country Status (10)

Country Link
US (1) US20180042873A1 (https=)
EP (1) EP3218354A4 (https=)
JP (1) JP2017535546A (https=)
CN (1) CN107207417A (https=)
AU (1) AU2015346076A1 (https=)
CA (1) CA2966950A1 (https=)
IL (1) IL252086A0 (https=)
SG (1) SG11201703801SA (https=)
TW (1) TW201716059A (https=)
WO (1) WO2016077787A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110790787A (zh) * 2019-11-12 2020-02-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
WO2015065919A1 (en) 2013-10-28 2015-05-07 The Regents Of The University Of California Treatment of metastatic prostate cancer
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
CA3022684A1 (en) 2016-05-13 2017-11-16 Aeromics, Inc. Crystals
BR112022003434A2 (pt) * 2019-08-23 2022-05-24 Dae Woong Pharma Composição de liberação retardada de niclosamida e uso antiviral da mesma

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2009054439A1 (ja) * 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
US20100113770A1 (en) * 2002-06-06 2010-05-06 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
CN101790306A (zh) * 2007-02-17 2010-07-28 哈佛学院董事会 用于进行组织保存的组合物以及方法
CN101849953A (zh) * 2000-12-18 2010-10-06 株式会社医药分子设计研究所 炎症性细胞因子产生游离抑制剂
US20120238623A1 (en) * 2011-03-14 2012-09-20 Chandraratna Roshantha A Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
WO2013169939A2 (en) * 2012-05-08 2013-11-14 Aeromics, Llc New methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101849953A (zh) * 2000-12-18 2010-10-06 株式会社医药分子设计研究所 炎症性细胞因子产生游离抑制剂
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
US20100113770A1 (en) * 2002-06-06 2010-05-06 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
CN101790306A (zh) * 2007-02-17 2010-07-28 哈佛学院董事会 用于进行组织保存的组合物以及方法
WO2009054439A1 (ja) * 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
US20120238623A1 (en) * 2011-03-14 2012-09-20 Chandraratna Roshantha A Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
WO2013169939A2 (en) * 2012-05-08 2013-11-14 Aeromics, Llc New methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110790787A (zh) * 2019-11-12 2020-02-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途

Also Published As

Publication number Publication date
CA2966950A1 (en) 2016-05-19
AU2015346076A1 (en) 2017-06-15
WO2016077787A1 (en) 2016-05-19
EP3218354A1 (en) 2017-09-20
IL252086A0 (en) 2017-07-31
US20180042873A1 (en) 2018-02-15
EP3218354A4 (en) 2018-06-13
TW201716059A (zh) 2017-05-16
SG11201703801SA (en) 2017-06-29
JP2017535546A (ja) 2017-11-30

Similar Documents

Publication Publication Date Title
CN107207417A (zh) 新方法
JP2017535546A5 (https=)
US8969297B2 (en) Methods and compositions for the induction of hypothermia
JP2006522052A (ja) ミコフェノール酸、その塩またはプロドラッグの非経腸製剤
CA2896073C (en) Stimulation and enhancement of regeneration of tissues
CN102083443B (zh) 调节肌动蛋白细胞骨架重排和细胞间间隙形成的方法
CN100479814C (zh) 促淋巴细胞归巢剂在制备用于治疗移植物功能恢复延迟的药物中的用途
CA3092596C (en) Novel aminothiol reduction of ischemia-reperfusion-induced cell death
JP2021107447A (ja) 移植片拒絶反応の処置方法
US20170007624A1 (en) Methods and compositions for stimulation and enhancement of regeneration of tissues
CN103068370A (zh) 用于改善的器官移植物保存和接受性的组合物及方法
WO2002017959A2 (en) Immunosuppression using piceatannol and a calcineurin inhibitor
CA3037712A1 (en) Methods and compositions for stimulation and enhancement of regeneration of tissues
McKay The role of innate immunity in donor organ procurement
WO2017019214A1 (en) Donor organ pre-treatment formulation
Monache et al. Effect of pharmacological modulation of liver P-glycoproteins on cyclosporin A biliary excretion and cholestasis a study in isolated perfused rat liver
US20040033941A1 (en) Immunosuppression using piceatannol and a calcineurin inhibitor
KR20250120401A (ko) 이식물 및 수혜자의 생존을 연장하기 위한 조성물 및 방법
Hoogendijk-van den Akker et al. Sirolimus and proteinuria in Thy-1.1 transgenic mouse
Balachandran et al. CHOP mediates cold ischemia and reperfusion injury in steatotic hepatocytes
JP2019522052A (ja) 抗細菌組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926